OBJECTIVEVascular procedures involving groin incisions for femoral exposure often have complications that delay wound healing. These complications include but are not limited to development of seromas, hematomas, or infection requiring reintervention leading to readmission, increased length of stay, and increased morbidity & mortality, including limb loss. In this prospective study, we evaluate the utility of CellerateRX® surgical powder in preventing postoperative groin complications. We compare outcomes of groin incisions that received standard surgical wound care and those that were additionally packed with CellerateRX® powder. METHODSGroin incisions required for femoral exposure in vascular surgery procedures were considered. The control group included cases between 2020-2021. Exclusion criteria included patients less than 18 years of age, those with a bovine allergy, those with an active groin infection, or those undergoing a repeat femoral exposure. Bilateral groin incisions were counted as two separate constituents in the overall sample. The perioperative protocol in the management of these patients included one-hour preoperative vancomycin (15 mg/kg IV)/ceftriaxone (2 g IV), double skin preparation with 4% chlorhexidine, hair removal with surgical clippers, IobanTM, postoperative doxycycline (100 mg PO/IV BID for 24 hours), and negative pressure wound therapy or a muscle flap in high-risk patients. Patients between 2022-2023 who met the described inclusion criteria were enrolled into the experimental group. The only change to the perioperative protocol of the experimental group was the addition of CellerateRX® powder to the surgical wound before closure. Patients were followed for 6 months. The primary outcome was the number of groin complications that required return to the operating room (e.g., seroma, hematoma, infection). RESULTSThe control group consisted of 137 groins, 17 (13%) of which developed complications—7 (5.2%) seromas, two (1.5%) hematomas, five (3.7%) soft tissue infections, and three (2.2%) skin necrosis cases. The treatment group consisted of 20 groins, 3 (15%) of which developed complications—two seromas and one soft tissue infection. A two-tailed Fisher’s exact test demonstrated no statistically significant association between the presence of complications and the treatment group (p=.49, α=.05). CONCLUSIONSBased on the results of this study, we cannot conclude that packing wounds with CellerateRX® powder alters the risk of developing postoperative groin complications compared to standard wound care. Although the number of hematomas and skin necrosis were not observed in the treatment group, the observed differences may be due to the small sample size.
Read full abstract